[ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology]

Neoadjuvant chemotherapy (NAC) is recommended for localized muscle-invasive bladder cancer when patients are fit for cisplatin-based chemotherapy. A pathological complete response can be observed, corresponding to ypT0N0 stage on the radical cystectomy specimen. This review discusses the incidence, prognosis and potential therapeutic impact of complete response on pathological specimen in NAC treated patients.

A comprehensive review of the literature was conducted using Medline database, with no time frame. The articles were selected using the following keywords association: "Bladder cancer" (Mesh) AND "Neoadjuvant chemotherapy" (Mesh) AND "pT0" (Mesh).

After NAC, ypT0N0 rates vary from 9 to 46% among the series, reported rates that are higher compared to those of pT0 without NAC administration. The incidence depends on the chemotherapy regimen (maximal local effect with cisplatin-based chemotherapy) and the pathological type of the disease (presence of variant histologies). Molecular analyses of bladder cancer could probably help in the near future to identify and predict NAC responders. Pathological complete response is associated with a favorable prognosis in terms of recurrence-free and overall survival. Nevertheless, disease recurrences are still observed in 10-15% of cases, which underlies the importance of local treatment and close follow-up even in these patients.

ypT0N0 rate is approximately 25% after NAC, that is 4.3 higher than after bladder resection alone. The prognosis is better than that with residual tumor on specimen and is comparable to that of pT0 without NAC administration.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2018 Sep 08 [Epub ahead of print]

G Pignot, N Houédé, M Roumiguié, F Audenet, S Brunelle, P Colin, E Compérat, S Larré, A Masson-Lecomte, Y Neuzillet, E Xylinas, A Méjean, M Rouprêt, les membres du CCAFU Vessie

Service de chirurgie oncologique 2, institut Paoli-Calmettes, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France. Electronic address: ., Département d'oncologie médicale, Montpellier université, CHU de Caremaux, 30900 Nîmes, France., Département d'urologie, CHU de Rangueil, 31400 Toulouse, France., Service d'urologie, université Paris Descartes, hôpital Européen Georges-Pompidou, Assistance publique des hôpitaux de Paris (AP-HP), 75015 Paris, France., Service de radiologie, institut Paoli-Calmettes, 13009 Marseille, France., Service d'urologie, hôpital privé de la Louvière, 59800 Lille, France., GRC n°5, ONCOTYPE-URO, service d'anatomie pathologique, Sorbonne université, hôpital universitaire Est Parisien (HUEP), hôpital Tenon, 75020 Paris, France., Service d'urologie, CHU de Reims, 51100 Reims, France., Service d'urologie, université Paris-Diderot, hôpital Saint-Louis, 75010 Paris, France., Service d'urologie, université de Versailles-Saint-Quentin-en-Yvelines, hôpital Foch, 92150 Suresnes, France., Service d'urologie, université Paris Descartes, hôpital Bichat-Claude Bernard, Assistance publique des hôpitaux de Paris (AP-HP), 75018 Paris, France., GRC n°5, ONCOTYPE-URO, Sorbonne Université, hôpital Pitié-Salpêtrière, Assistance publique des hôpitaux de Paris (AP-HP), 75013 Paris, France.